[go: up one dir, main page]

MX2024011328A - Proteinas de union gfral y uso de las mismas - Google Patents

Proteinas de union gfral y uso de las mismas

Info

Publication number
MX2024011328A
MX2024011328A MX2024011328A MX2024011328A MX2024011328A MX 2024011328 A MX2024011328 A MX 2024011328A MX 2024011328 A MX2024011328 A MX 2024011328A MX 2024011328 A MX2024011328 A MX 2024011328A MX 2024011328 A MX2024011328 A MX 2024011328A
Authority
MX
Mexico
Prior art keywords
methods
binding proteins
protein
gfral
antibodies
Prior art date
Application number
MX2024011328A
Other languages
English (en)
Inventor
Wenyan Shen
Jie Tang
Yan Wang
Hugo Matern
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of MX2024011328A publication Critical patent/MX2024011328A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción provee proteínas de unión tales como anticuerpos, que se unen a una proteína del Tipo de Receptor Alfa de la Familia GDNF (GFRAL), que incluye la proteína GFRAL humana, y métodos de su uso.
MX2024011328A 2016-03-31 2018-09-21 Proteinas de union gfral y uso de las mismas MX2024011328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316516P 2016-03-31 2016-03-31
PCT/US2017/020654 WO2017172260A1 (en) 2016-03-31 2017-03-03 Binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2024011328A true MX2024011328A (es) 2024-11-08

Family

ID=59966343

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011503A MX2018011503A (es) 2016-03-31 2017-03-03 Proteinas de union y metodos de uso de las mismas.
MX2024011328A MX2024011328A (es) 2016-03-31 2018-09-21 Proteinas de union gfral y uso de las mismas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011503A MX2018011503A (es) 2016-03-31 2017-03-03 Proteinas de union y metodos de uso de las mismas.

Country Status (19)

Country Link
US (4) US10174119B2 (es)
EP (1) EP3436068A4 (es)
JP (3) JP7021099B2 (es)
KR (2) KR102630655B1 (es)
CN (2) CN109715206B (es)
AU (3) AU2017241161B2 (es)
BR (1) BR112018068898A2 (es)
CA (1) CA3016035A1 (es)
CL (1) CL2018002687A1 (es)
CO (1) CO2018009995A2 (es)
IL (1) IL261666B2 (es)
MX (2) MX2018011503A (es)
MY (1) MY194669A (es)
NZ (1) NZ785098A (es)
PE (1) PE20190126A1 (es)
PH (1) PH12018501882A1 (es)
SG (1) SG11201807279QA (es)
TW (2) TWI897070B (es)
WO (1) WO2017172260A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201807279QA (en) 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
AU2017342028A1 (en) * 2016-10-12 2019-04-11 Janssen Biotech, Inc. Methods for screening for modulators of GDF15-like biological activity
WO2020031149A2 (en) * 2018-08-10 2020-02-13 Novartis Ag Gfral extracellular domains and methods of use
AU2020219142B2 (en) * 2019-02-05 2025-11-06 Syracuse University Peptide ligands of the GDNF family receptor a-like (GFRAL) receptor
US20220213187A1 (en) * 2019-05-08 2022-07-07 Agilvax Inc. Compositions and methods related to xct antibodies
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
US20220332805A1 (en) * 2019-09-11 2022-10-20 University Of Cincinnati Treatment of Skin Blistering Diseases Using Antibodies
JP7495529B2 (ja) * 2020-06-04 2024-06-04 テグ キョンプク インスティテュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌ拮抗抗体及びその用途
KR102708796B1 (ko) 2020-06-04 2024-09-26 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
WO2022178416A1 (en) * 2021-02-22 2022-08-25 Northwestern University Anti-cd73 monoclonal antibodies
WO2022207785A1 (en) * 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
JP2024511853A (ja) 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤
KR20240035764A (ko) * 2021-06-30 2024-03-18 상하이 제이엠티-바이오 테크노로지 컴퍼니 리미티드 항-gfral 항체 및 이의 응용
EP4384545A1 (en) 2021-08-10 2024-06-19 BYOMass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023039359A1 (en) 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia
KR102864956B1 (ko) 2021-09-24 2025-09-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
WO2023048425A1 (ko) * 2021-09-24 2023-03-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
EP4452316A1 (en) 2021-12-22 2024-10-30 BYOMass Inc. Targeting gdf15-gfral pathway
KR20240139079A (ko) * 2022-02-03 2024-09-20 아이쥐엠 바이오사이언스 인코포레이티드 항-cd38 결합 분자 및 이의 용도
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
AU2023243321A1 (en) * 2022-03-28 2024-10-31 Coherus Oncology, Inc. Anti-ilt4 compositions and methods
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica
US20250074991A1 (en) 2023-07-31 2025-03-06 Ngm Biopharmaceuticals, Inc. Methods of treating nausea and vomiting disorders using anti-gfral antibodies
CN117209596B (zh) * 2023-09-01 2024-11-26 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒p72蛋白中和活性单克隆抗体2c9及其应用
WO2025179086A1 (en) * 2024-02-23 2025-08-28 Children's National Medical Center Anti-ret antibodies as cancer therapeutics and diagnostic tools
WO2025244462A1 (ko) * 2024-05-24 2025-11-27 한국과학기술원 Gfral을 표적으로 하는 단일클론 항체 및 이의 용도

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
JPH07258293A (ja) 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
AU1830195A (en) 1994-12-15 1996-07-03 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
EP0833912B1 (en) 1995-06-22 2009-02-25 St Vincent's Hospital Sydney Limited Novel tgf-beta like cytokine
JP2000501924A (ja) 1995-11-13 2000-02-22 イバネズ，カルロス 神経膠細胞系由来神経栄養因子のレセプター類
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
BR9711763A (pt) 1996-09-11 1999-08-24 Ortho Mcneil Pharm Inc Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos
WO1998050555A2 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
WO1998052591A1 (en) 1997-05-22 1998-11-26 Cephalon Inc. Glial cell line-derived neurotrophic factor receptors
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
WO2000005259A1 (en) 1998-07-23 2000-02-03 Smithkline Beecham Corporation Secreted cysteine rich protein-6 (scrp-6)
US6905817B1 (en) 1998-10-01 2005-06-14 Licestia Ltd. Ret-independent signaling pathway for GDNF
AU5994099A (en) 1998-10-01 2000-04-26 Urmas Arumae A novel ret-independent signaling pathway for gdnf
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60032355T2 (de) 1999-05-17 2007-04-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE
US6866851B1 (en) 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
AU5018201A (en) 2000-04-20 2001-11-07 St Vincents Hospital Sydney Lt Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
CA2433439A1 (en) 2000-12-29 2002-08-15 Curagen Corporation Proteins and nucleic acids encoding same
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
JP4524074B2 (ja) 2001-03-09 2010-08-11 アーナソン， バリー ジー． 低親和性Ｆｃγレセプターを標的化する重合体の免疫グロブリン融合タンパク質
CN1970078A (zh) 2001-05-11 2007-05-30 安姆根有限公司 与tall－1结合的肽和相关分子
GB0115195D0 (en) 2001-06-21 2001-08-15 Bae Systems Plc Split-pin drill jig
US20030053431A1 (en) 2001-09-10 2003-03-20 Lila Madour Method for performing handoff in a radio telecommunications network
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
EP1506215B1 (en) 2002-03-05 2016-11-30 Genentech, Inc. Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
US20100285016A1 (en) 2002-03-05 2010-11-11 Genentech, Inc. PRO34128 nucleic acids
US7576185B2 (en) * 2002-03-05 2009-08-18 Genentech, Inc. PRO34128 antibodies
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
AU2003295424A1 (en) 2002-11-08 2004-06-03 Barnes-Jewish Hospital Methods and compositions for prostate epithelial cell differentiation
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
CN1241941C (zh) 2003-11-21 2006-02-15 中国科学院上海生命科学研究院 一种促进神经分化和抗细胞凋亡的蛋白质及其编码基因
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
AU2006206848B2 (en) 2005-01-24 2012-05-31 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
WO2007030930A1 (en) 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
PL2650305T3 (pl) 2006-03-24 2024-09-16 Bioverativ Therapeutics Inc. PC5 jako enzym przetwarzający propeptyd czynnika IX
US8974748B2 (en) 2007-04-05 2015-03-10 Corning Incorporated Dual inlet microchannel device and method for using same
AU2007297565A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
JP2009544697A (ja) 2006-07-26 2009-12-17 ペプスキャン システムズ ベー．フェー． 免疫原性化合物及びタンパク質擬態物
CA2660691C (en) 2006-08-04 2020-01-14 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
RU2461569C2 (ru) * 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
US8278096B2 (en) 2007-04-25 2012-10-02 Stem Cells Spin Spolka Akcyjna Stem cell lines from deer antlers, their application and culture methods
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
CA2694863A1 (en) 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
WO2009046495A1 (en) 2007-10-09 2009-04-16 St Vincent's Hospital Sydney Limited A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
ES2543985T3 (es) 2007-10-22 2015-08-26 St Vincent's Hospital Sydney Limited Métodos de pronóstico
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
JP2011509403A (ja) 2008-01-08 2011-03-24 エフ．ホフマン−ラ ロシュ アーゲー Ｇｄｆ−１５に基づいて救急室を受診する患者のリスクを評価するための手段及び方法
WO2009126709A1 (en) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands for the glp-1 receptor and methods for discovery thereof
EP2279419A1 (en) 2008-05-20 2011-02-02 Roche Diagnostics GmbH Gdf-15 as biomarker in type 1 diabetes
JP2011528115A (ja) 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
JP5444363B2 (ja) 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
CN102333862B (zh) 2008-10-31 2018-04-27 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
SG173632A1 (en) 2009-02-12 2011-09-29 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
GB0902737D0 (en) 2009-02-19 2009-04-01 Univ Gent GDF15 as a differential marker for spondyloarthropathy
KR101558642B1 (ko) 2009-02-24 2015-10-12 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드
JP5823954B2 (ja) 2009-05-05 2015-11-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体及びその使用
AU2010270844A1 (en) 2009-07-08 2011-12-22 Amgen Inc. Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering
US20130323835A1 (en) 2009-07-15 2013-12-05 Zirus, Inc. Mammalian Genes Involved in Infection
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
WO2011057120A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
US20120321557A1 (en) * 2010-02-26 2012-12-20 Forerunner Pharma Research Co., Ltd. Anti-icam3 antibody and use thereof
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP5791335B2 (ja) 2010-04-07 2015-10-07 花王株式会社 オルガノポリシロキサン化合物の製造方法
WO2011127458A2 (en) 2010-04-09 2011-10-13 University Of Southern California Systems and methods of cell activated, controlled release delivery of growth factors for tissue repair and regeneration
EP2383571A1 (en) 2010-05-02 2011-11-02 Prof. Hess Medical Consulting GmbH Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer
ES2534921T3 (es) 2010-08-26 2015-04-30 F. Hoffmann-La Roche Ag Uso de biomarcadores en la evaluación de la transición temprana de la hipertensión arterial a la insuficiencia cardíaca
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
DK2697257T3 (en) 2011-04-13 2017-01-30 Bristol Myers Squibb Co FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
RU2641256C2 (ru) 2011-06-30 2018-01-16 Чугаи Сейяку Кабусики Кайся Гетеродимеризованный полипептид
KR20140045440A (ko) 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
WO2013012648A1 (en) * 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9492448B2 (en) 2012-06-20 2016-11-15 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
WO2014000042A1 (en) 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
UY34905A (es) * 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
EP2875051B1 (en) * 2012-07-19 2019-02-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies
EP2882774B1 (en) 2012-08-08 2018-10-03 Roche Glycart AG Interleukin-10 fusion proteins and uses thereof
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
EP3590537A1 (en) 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
AU2013334583B2 (en) 2012-10-24 2018-09-13 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
WO2014086365A1 (en) 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
JP6758832B2 (ja) * 2012-12-21 2020-09-30 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｇｄｆ１５抗体
DE102013100322A1 (de) 2013-01-14 2014-07-17 Claas Selbstfahrende Erntemaschinen Gmbh Schneidwerk
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
WO2014140374A2 (en) * 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
AU2014233494B2 (en) 2013-03-15 2018-10-04 Genentech, Inc. IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use
RU2015155601A (ru) 2013-06-10 2017-07-14 Мерк Шарп И Доум Корп. Нейтрализующие цитомегаловирус (цмв) антигенсвязывающие белки
MX369152B (es) 2013-07-31 2019-10-30 Amgen Inc Construcciones del factor de diferenciación de crecimiento 15 (gdf-15).
EP3172237A2 (en) * 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG11201700378PA (en) 2014-07-30 2017-02-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
DK3212226T3 (da) 2014-10-31 2020-06-15 Ngm Biopharmaceuticals Inc Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
CN108697795A (zh) 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
CN109069636A (zh) * 2016-03-04 2018-12-21 恩格姆生物制药公司 用于调节体重的组合物和方法
SG11201807279QA (en) * 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
AU2017342028A1 (en) 2016-10-12 2019-04-11 Janssen Biotech, Inc. Methods for screening for modulators of GDF15-like biological activity
EP3841121A2 (en) 2018-08-20 2021-06-30 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
JP7495529B2 (ja) 2020-06-04 2024-06-04 テグ キョンプク インスティテュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌ拮抗抗体及びその用途
US11845791B2 (en) 2021-03-08 2023-12-19 Medimmune, Llc Antibodies directed against GDF-15
JP2024511853A (ja) 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤
WO2022207785A1 (en) 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
WO2023039359A1 (en) 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia

Also Published As

Publication number Publication date
KR20180130524A (ko) 2018-12-07
JP2019513018A (ja) 2019-05-23
TWI897070B (zh) 2025-09-11
KR102630655B1 (ko) 2024-01-30
CO2018009995A2 (es) 2018-12-14
IL261666B1 (en) 2024-05-01
PH12018501882A1 (en) 2019-01-28
JP2024156852A (ja) 2024-11-06
RU2018132739A (ru) 2020-04-30
US20220073627A1 (en) 2022-03-10
TWI815793B (zh) 2023-09-21
KR102370762B1 (ko) 2022-03-04
NZ745635A (en) 2024-03-22
TW201809011A (zh) 2018-03-16
US20170306031A1 (en) 2017-10-26
US10975154B2 (en) 2021-04-13
MY194669A (en) 2022-12-12
IL261666A (en) 2018-10-31
AU2017241161A1 (en) 2018-09-20
NZ785098A (en) 2025-09-26
IL261666B2 (en) 2024-09-01
WO2017172260A1 (en) 2017-10-05
WO2017172260A8 (en) 2017-12-28
AU2017241161B2 (en) 2022-05-26
CA3016035A1 (en) 2017-10-05
MX2018011503A (es) 2018-11-09
JP7021099B2 (ja) 2022-02-18
CN117986363A (zh) 2024-05-07
US12180289B2 (en) 2024-12-31
CN109715206B (zh) 2023-11-07
SG11201807279QA (en) 2018-09-27
EP3436068A1 (en) 2019-02-06
BR112018068898A2 (pt) 2019-01-22
PE20190126A1 (es) 2019-01-17
US20190092866A1 (en) 2019-03-28
AU2022224794A1 (en) 2022-09-22
KR20220032645A (ko) 2022-03-15
CN109715206A (zh) 2019-05-03
JP7610541B2 (ja) 2025-01-08
US10174119B2 (en) 2019-01-08
RU2018132739A3 (es) 2020-09-02
AU2022224794B2 (en) 2025-07-03
US20250188174A1 (en) 2025-06-12
EP3436068A4 (en) 2020-01-15
TW202423985A (zh) 2024-06-16
JP2022088355A (ja) 2022-06-14
CL2018002687A1 (es) 2019-05-10
AU2025234197A1 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
MX2024011328A (es) Proteinas de union gfral y uso de las mismas
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
IL271110A (en) Antibodies specific for flt3 and their uses
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
MX2018016404A (es) Anticuerpos de union a cd3.
MX2016006709A (es) Moduladores de aplnr y usos de estos.
BR112016022841A2 (pt) cadeia j modificada
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
CL2017000212A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
CO2019013718A2 (es) Anticuerpos anti-trkb
MX2019004371A (es) Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos.
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EA201692395A1 (ru) Новые соединения
DK3681911T3 (da) Bindende proteiner til den humane trombinreceptor PAR4
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение